GRI Bio Statistics
Share Statistics
GRI Bio has 8.93M shares outstanding. The number of shares has increased by 815.13% in one year.
| Shares Outstanding | 8.93M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 205.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 8.93M |
| Failed to Deliver (FTD) Shares | 4.17K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 924.63K, so 10.35% of the outstanding shares have been sold short.
| Short Interest | 924.63K |
| Short % of Shares Out | 10.35% |
| Short % of Float | 10.36% |
| Short Ratio (days to cover) | 0.1 |
Valuation Ratios
The PE ratio is -1.14 and the forward PE ratio is -0.32.
| PE Ratio | -1.14 |
| Forward PE | -0.32 |
| PS Ratio | 0.69 |
| Forward PS | 0.7 |
| PB Ratio | 57.58 |
| P/FCF Ratio | -1.66 |
| PEG Ratio | n/a |
Enterprise Valuation
GRI Bio Inc. has an Enterprise Value (EV) of -552.39K.
| EV / Earnings | 0.04 |
| EV / Sales | -0.03 |
| EV / EBITDA | 0.05 |
| EV / EBIT | 0.05 |
| EV / FCF | 0.06 |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.09 |
| Quick Ratio | 1.09 |
| Debt / Equity | 0.05 |
| Total Debt / Capitalization | 5.13 |
| Cash Flow / Debt | -652.86 |
| Interest Coverage | -5.47 |
Financial Efficiency
Return on equity (ROE) is -50.34% and return on capital (ROIC) is -5055.7%.
| Return on Equity (ROE) | -50.34% |
| Return on Assets (ROA) | -4.41% |
| Return on Capital (ROIC) | -5055.7% |
| Revenue Per Employee | 5.44M |
| Profits Per Employee | -3.26M |
| Employee Count | 4 |
| Asset Turnover | 7.36 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 2.77M |
| Effective Tax Rate | -0.21 |
Stock Price Statistics
The stock price has increased by -97.21% in the last 52 weeks. The beta is -1.8, so GRI Bio 's price volatility has been lower than the market average.
| Beta | -1.8 |
| 52-Week Price Change | -97.21% |
| 50-Day Moving Average | 0.8 |
| 200-Day Moving Average | 2.16 |
| Relative Strength Index (RSI) | 46.69 |
| Average Volume (20 Days) | 4.16M |
Income Statement
In the last 12 months, GRI Bio had revenue of 21.77M and earned -13.04M in profits. Earnings per share was -28.25.
| Revenue | 21.77M |
| Gross Profit | 21.71M |
| Operating Income | -11.39M |
| Net Income | -13.04M |
| EBITDA | -10.90M |
| EBIT | -11.39M |
| Earnings Per Share (EPS) | -28.25 |
Balance Sheet
The company has 1.81M in cash and 14.00K in debt, giving a net cash position of 1.79M.
| Cash & Cash Equivalents | 1.81M |
| Total Debt | 14.00K |
| Net Cash | 1.79M |
| Retained Earnings | -31.53M |
| Total Assets | 5.46M |
| Working Capital | 3.61M |
Cash Flow
In the last 12 months, operating cash flow was -9.14M and capital expenditures -8.00K, giving a free cash flow of -9.00M.
| Operating Cash Flow | -9.14M |
| Capital Expenditures | -8.00K |
| Free Cash Flow | -9.00M |
| FCF Per Share | -19.49 |
Margins
Gross margin is 99.74%, with operating and profit margins of -52.31% and -59.89%.
| Gross Margin | 99.74% |
| Operating Margin | -52.31% |
| Pretax Margin | -59.89% |
| Profit Margin | -59.89% |
| EBITDA Margin | -50.07% |
| EBIT Margin | -52.31% |
| FCF Margin | -41.34% |
Dividends & Yields
GRI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3817.57% |
| FCF Yield | -136.04% |
Analyst Forecast
The average price target for GRI is $11.5, which is 1454.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $11.5 |
| Price Target Difference | 1454.1% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 18, 2024. It was a backward split with a ratio of 1:13.
| Last Split Date | Jun 18, 2024 |
| Split Type | backward |
| Split Ratio | 1:13 |
Scores
| Altman Z-Score | -10.44 |
| Piotroski F-Score | 2 |